Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics

Progress in Neurobiology

Volumn 92, Issue 1, 2010, Pages 1-18

  Duce, James A ^a,b   Bush, Ashley I ^a,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Ageing; Alzheimer's disease; Copper; Iron; Metal protein attenuating compounds; Zinc

Indexed keywords

8 QUINOLINOL; ALPHA TOCOPHEROL; ALUMINUM; ANTIOXIDANT; ASCORBIC ACID; CHELATING AGENT; CLIOQUINOL; COPPER; CURCUMIN; DEFEROXAMINE; DIACETYLBIS[N(4) METHYL 3 THIOSEMICARBAZONATO]COPPER; DP 109; DP 460; ESTROGEN; FLAVONOID; GINKGO BILOBA EXTRACT; GLYOXALBIS[N(4) METHYL 3 THIOSEMICARBAZONATO]COPPER; IONOPHORE; IRON; LEAD; MELATONIN; METAL ION; PLATINUM (4,7 DIPHENYL 1,10 PHENANTHROLINE) CHLORIDE; PYRROLIDINE DITHIOCARBAMATE; THIOSEMICARBAZONE; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEGENERATIVE DISEASE; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; LEARNING; MEMORY; MYELINATION; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBACUTE MYELOOPTIC NEUROPATHY;

EID: 77953940704     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2010.04.003     Document Type: Review

References (334)

1. Abramov A.Y., Canevari L., Duchen M.R. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J. Neurosci. 2003, 23:5088-5095.
2. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
3. Adlard P.A., Parncutt J.M., Finkelstein D.I., Bush A.I. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?. J. Neurosci. 2010, 30:1631-1636.
4. Ahluwalia N., Gordon M.A., Handte G., Mahlon M., Li N.Q., Beard J.L., Weinstock D., Ross A.C. Iron status and stores decline with age in Lewis rats. J. Nutr. 2000, 130:2378-2383.
5. Alfrey A.C., LeGendre G.R., Kaehny W.D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med. 1976, 294:184-188.
6. Ali F.E., Separovic F., Barrow C.J., Cherny R.A., Fraser F., Bush A.I., Masters C.L., Barnham K.J. Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J. Pept. Sci. 2005, 11:353-360.
7. An W.L., Bjorkdahl C., Liu R., Cowburn R.F., Winblad B., Pei J.J. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J. Neurochem. 2005, 92:1104-1115.
8. Angeletti B., Waldron K.J., Freeman K.B., Bawagan H., Hussain I., Miller C.C., Lau K.F., Tennant M.E., Dennison C., Robinson N.J., Dingwall C. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J. Biol. Chem. 2005, 280:17930-17937.
9. Armendariz A.D., Gonzalez M., Loguinov A.V., Vulpe C.D. Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol. Genomics 2004, 20:45-54.
10. Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Bacarra N.M., Romano D.M., Hartshorn M.A., Tanzi R.E., Bush A.I. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 1998, 273:12817-12826.
11. Atwood C.S., Perry G., Zeng H., Kato Y., Jones W.D., Ling K.Q., Huang X., Moir R.D., Wang D., Sayre L.M., Smith M.A., Chen S.G., Bush A.I. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 2004, 43:560-568.
12. Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., Tanzi R.E., Bush A.I. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 2000, 75:1219-1233.
13. Barnham K.J., Haeffner F., Ciccotosto G.D., Curtain C.C., Tew D., Mavros C., Beyreuther K., Carrington D., Masters C.L., Cherny R.A., Cappai R., Bush A.I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 2004, 18:1427-1429.
14. Barnham K.J., Kenche V.B., Ciccotosto G.D., Smith D.P., Tew D.J., Liu X., Perez K., Cranston G.A., Johanssen T.J., Volitakis I., Bush A.I., Masters C.L., White A.R., Smith J.P., Cherny R.A., Cappai R. Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6813-6818.
15. Barnham K.J., McKinstry W.J., Multhaup G., Galatis D., Morton C.J., Curtain C.C., Williamson N.A., White A.R., Hinds M.G., Norton R.S., Beyreuther K., Masters C.L., Parker M.W., Cappai R. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J. Biol. Chem. 2003, 278:17401-17407.
16. Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., Marder S.R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 1997, 15:29-35.
17. Bartzokis G., Mintz J., Sultzer D., Marx P., Herzberg J.S., Phelan C.K., Marder S.R. In vivo MR evaluation of age-related increases in brain iron. AJNR Am. J. Neuroradiol. 1994, 15:1129-1138.
18. Bartzokis G., Tishler T.A., Lu P.H., Villablanca P., Altshuler L.L., Carter M., Huang D., Edwards N., Mintz J. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 2007, 28:414-423.
19. Baruch-Suchodolsky R., Fischer B. Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 2009, 48:4354-4370.
20. Basha M.R., Murali M., Siddiqi H.K., Ghosal K., Siddiqi O.K., Lashuel H.A., Ge Y.W., Lahiri D.K., Zawia N.H. Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J. 2005, 19:2083-2084.
21. Basha M.R., Wei W., Bakheet S.A., Benitez N., Siddiqi H.K., Ge Y.W., Lahiri D.K., Zawia N.H. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J. Neurosci. 2005, 25:823-829.
22. Basun H., Forssell L.G., Wetterberg L., Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J. Neural. Transm. Park Dis. Dement. Sect. 1991, 3:231-258.
23. Baum L., Chan I.H., Cheung S.K., Goggins W.B., Mok V., Lam L., Leung V., Hui E., Ng C., Woo J., Chiu H.F., Zee B.C., Cheng W., Chan M.H., Szeto S., Lui V., Tsoh J., Bush A.I., Lam C.W., Kwok T. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals 2010, 23:173-179.
24. Bayer T.A., Schafer S., Simons A., Kemmling A., Kamer T., Tepest R., Eckert A., Schussel K., Eikenberg O., Sturchler-Pierrat C., Abramowski D., Staufenbiel M., Multhaup G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14187-14192.
25. Behl C., Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic. Biol. Med. 2002, 33:182-191.
26. Bellingham S.A., Ciccotosto G.D., Needham B.E., Fodero L.R., White A.R., Masters C.L., Cappai R., Camakaris J. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J. Neurochem. 2004, 91:423-428.
27. Bellingham S.A., Lahiri D.K., Maloney B., La Fontaine S., Multhaup G., Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J. Biol. Chem. 2004, 279:20378-20386.
28. Benvenisti-Zarom L., Chen J., Regan R.F. The oxidative neurotoxicity of clioquinol. Neuropharmacology 2005, 49:687-694.
29. Bertini I. Biological Inorganic Chemistry: Structure and Reactivity 2007, University Science Books, Sausalito, CA.
30. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
31. Bishop G.M., Robinson S.R., Liu Q., Perry G., Atwood C.S., Smith M.A. Iron: a pathological mediator of Alzheimer disease?. Dev. Neurosci. 2002, 24:184-187.
32. Bjorkdahl C., Sjogren M.J., Winblad B., Pei J.J. Zinc induces neurofilament phosphorylation independent of p70 S6 kinase in N2a cells. Neuroreport 2005, 16:591-595.
33. Bondiolotti G., Sala M., Pollera C., Gervasoni M., Puricelli M., Ponti W., Bareggi S.R. Pharmacokinetics and distribution of clioquinol in golden hamsters. J. Pharm. Pharmacol. 2007, 59:387-393.
34. Bouras C., Giannakopoulos P., Good P.F., Hsu A., Hof P.R., Perl D.P. A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Eur. Neurol. 1997, 38:53-58.
35. Brown D.R., Kozlowski H. Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases. Dalton Trans. 2004, 1907-1917.
36. Buckley C.A., Rouhani F.N., Kaler M., Adamik B., Hawari F.I., Levine S.J. Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L1132-1138.
37. Bunker V.W., Hinks L.J., Stansfield M.F., Lawson M.S., Clayton B.E. Metabolic balance studies for zinc and copper in housebound elderly people and the relationship between zinc balance and leukocyte zinc concentrations. Am. J. Clin. Nutr. 1987, 46:353-359.
38. Bush A.I., Multhaup G., Moir R.D., Williamson T.G., Small D.H., Rumble B., Pollwein P., Beyreuther K., Masters C.L. A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J. Biol. Chem. 1993, 268:16109-16112.
39. Bush A.I., Pettingell W.H., de Paradis M., Tanzi R.E., Wasco W. The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J. Biol. Chem. 1994, 269:26618-26621.
40. Bush A.I., Pettingell W.H., Paradis M.D., Tanzi R.E. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 1994, 269:12152-12158.
41. Bush A.I., Pettingell W.H., Multhaup G., d Paradis M., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994, 265:1464-1467.
42. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., Black R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 1998, 273:27765-27767.
43. Caccamo A., Oddo S., Sugarman M.C., Akbari Y., LaFerla F.M. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol. Aging 2005, 26:645-654.
44. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., Wong P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001, 4:233-234.
45. Canfield R.L., Henderson C.R., Cory-Slechta D.A., Cox C., Jusko T.A., Lanphear B.P. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N. Engl. J. Med. 2003, 348:1517-1526.
46. Cardoso S.M., Proenca M.T., Santos S., Santana I., Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 2004, 25:105-110.
47. Carri M.T., Ferri A., Cozzolino M., Calabrese L., Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res. Bull. 2003, 61:365-374.
48. Carson J.A., Turner A.J. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J. Neurochem. 2002, 81:1-8.
49. Castellani R.J., Moreira P.I., Liu G., Dobson J., Perry G., Smith M.A., Zhu X. Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem. Res. 2007, 32:1640-1645.
50. Cater M.A., McInnes K.T., Li Q.X., Volitakis I., La Fontaine S., Mercer J.F., Bush A.I. Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms. Biochem. J. 2008, 412:141-152.
51. Caughman S.W., Hentze M.W., Rouault T.A., Harford J.B., Klausner R.D. The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor. J. Biol. Chem. 1988, 263:19048-19052.
52. Chen K., Kazachkov M., Yu P.H. Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease. J. Neural. Transm. 2007, 114:835-839.
53. Cheng Y., Feng Z., Zhang Q.Z., Zhang J.T. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 2006, 27:129-139.
54. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
55. Cherny R.A., Barnham K.J., Lynch T., Volitakis I., Li Q.X., McLean C.A., Multhaup G., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J. Struct. Biol. 2000, 130:209-216.
56. Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 1999, 274:23223-23228.
57. Chowanadisai W., Kelleher S.L., Lonnerdal B. Zinc deficiency is associated with increased brain zinc import and LIV-1 expression and decreased ZnT-1 expression in neonatal rats. J. Nutr. 2005, 135:1002-1007.
58. Ciccotosto G.D., Tew D., Curtain C.C., Smith D., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., Barnham K.J. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J. Biol. Chem. 2004, 279:42528-42534.
59. Ciuculescu E.D., Mekmouche Y., Faller P. Metal-binding properties of the peptide APP170-188: a model of the ZnII-binding site of amyloid precursor protein (APP). Chemistry 2005, 11:903-909.
60. Clark C.M., Ewbank D., Lee V.M.-, Trojanowski J.Q. Molecular Pathology of Alzheimer's Disease: Neuronal Cytoskeletal Abnormalities 1998, Butterworth-Heinemann, Boston.
61. Clauberg M., Joshi J.G. Regulation of serine protease activity by aluminum: implications for Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:1009-1012.
62. Cole T.B., Wenzel H.J., Kafer K.E., Schwartzkroin P.A., Palmiter R.D. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1716-1721.
63. Collingwood J., Dobson J. Mapping and characterization of iron compounds in Alzheimer's tissue. J. Alzheimers Dis. 2006, 10:215-222.
64. Collingwood J.F., Mikhaylova A., Davidson M., Batich C., Streit W.J., Terry J., Dobson J. In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J. Alzheimers Dis. 2005, 7:267-272.
65. Connor J.R., Lee S.Y. HFE mutations and Alzheimer's disease. J. Alzheimers Dis. 2006, 10:267-276.
66. Connor J.R., Menzies S.L., St Martin S.M., Mufson E.J. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 1990, 27:595-611.
67. Connor J.R., Menzies S.L., St Martin S.M., Mufson E.J. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 1992, 31:75-83.
68. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 1995, 65:717-724.
69. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 1992, 31:327-335.
70. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
71. Cottrell D.A., Blakely E.L., Johnson M.A., Ince P.G., Turnbull D.M. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 2001, 57:260-264.
72. Crapper D.R., Krishnan S.S., Dalton A.J. Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science 1973, 180:511-513.
73. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
74. Cross J.B., Duca J.S., Kaminski J.J., Madison V.S. The active site of a zinc-dependent metalloproteinase influences the computed pK(a) of ligands coordinated to the catalytic zinc ion. J. Am. Chem. Soc. 2002, 124:11004-11007.
75. Crouch P.J., Hung L.W., Adlard P.A., Cortes M., Lal V., Filiz G., Perez K.A., Nurjono M., Caragounis A., Du T., Laughton K., Volitakis I., Bush A.I., Li Q.X., Masters C.L., Cappai R., Cherny R.A., Donnelly P.S., White A.R., Barnham K.J. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:381-386.
76. Crouch P.J., Tew D.J., Du T., Nguyen D.N., Caragounis A., Filiz G., Blake R.E., Trounce I.A., Soon C.P., Laughton K., Perez K.A., Li Q.X., Cherny R.A., Masters C.L., Barnham K.J., White A.R. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation. J. Neurochem. 2009, 108:1198-1207.
77. Cuajungco M.P., Faget K.Y., Huang X., Tanzi R.E., Bush A.I. Metal chelation as a potential therapy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 920:292-304.
78. Culotta V.C., Yang M., O'Halloran T.V. Activation of superoxide dismutases: putting the metal to the pedal. Biochim. Biophys. Acta 2006, 1763:747-758.
79. Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S., Beyreuther K., Barrow C.J., Masters C.L., Bush A.I., Barnham K.J. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 2001, 276:20466-20473.
80. Curtain C.C., Ali F.E., Smith D.G., Bush A.I., Masters C.L., Barnham K.J. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J. Biol. Chem. 2003, 278:2977-2982.
81. da Silva G.F., Lykourinou V., Angerhofer A., Ming L.J. Methionine does not reduce Cu(II)-beta-amyloid!--rectification of the roles of methionine-35 and reducing agents in metal-centered oxidation chemistry of Cu(II)-beta-amyloid. Biochim. Biophys. Acta 2009, 1792:49-55.
82. Danielsson J., Pierattelli R., Banci L., Graslund A. High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. FEBS J. 2007, 274:46-59.
83. Danzeisen R., Achsel T., Bederke U., Cozzolino M., Crosio C., Ferri A., Frenzel M., Gralla E.B., Huber L., Ludolph A., Nencini M., Rotilio G., Valentine J.S., Carri M.T. Superoxide dismutase 1 modulates expression of transferrin receptor. J. Biol. Inorg. Chem. 2006, 11:489-498.
84. Davis C.D., Milne D.B., Nielsen F.H. Changes in dietary zinc and copper affect zinc-status indicators of postmenopausal women, notably, extracellular superoxide dismutase and amyloid precursor proteins. Am. J. Clin. Nutr. 2000, 71:781-788.
85. De Deyn P.P., Hiramatsu M., Borggreve F., Goeman J., D'Hooge R., Saerens J., Mori A. Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis. Assoc. Disord. 1998, 12:26-32.
86. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003, 38:9-12.
87. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J. Biol. Inorg. Chem. 2002, 7:249-259.
88. Defeudis F.V. Bilobalide and neuroprotection. Pharmacol. Res. 2002, 46:565-568.
89. Deibel M.A., Ehmann W.D., Markesbery W.R. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. 1996, 143:137-142.
90. Deraeve C., Pitie M., Meunier B. Influence of chelators and iron ions on the production and degradation of H2O2 by beta-amyloid-copper complexes. J. Inorg. Biochem. 2006, 100:2117-2126.
91. Deshpande A., Kawai H., Metherate R., Glabe C.G., Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J. Neurosci. 2009, 29:4004-4015.
92. Di Vaira M., Bazzicalupi C., Orioli P., Messori L., Bruni B., Zatta P. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg. Chem. 2004, 43:3795-3797.
93. Dikalov S.I., Vitek M.P., Mason R.P. Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. Free Radic. Biol. Med. 2004, 36:340-347.
94. Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., Carey P.R. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003, 42:2768-2773.
95. Donnelly P.S., Caragounis A., Du T., Laughton K.M., Volitakis I., Cherny R.A., Sharples R.A., Hill A.F., Li Q.X., Masters C.L., Barnham K.J., White A.R. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J. Biol. Chem. 2008, 283:4568-4577.
96. Dorlet P., Gambarelli S., Faller P., Hureau C. Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-beta peptide: a key role of the first two N-terminus residues. Angew. Chem. Int. Ed. Engl. 2009, 48:9273-9276.
97. Drew S.C., Masters C.L., Barnham K.J. Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide--relevance to N-terminally truncated forms. J. Am. Chem. Soc. 2009, 131:8760-8761.
98. Drew S.C., Noble C.J., Masters C.L., Hanson G.R., Barnham K.J. Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J. Am. Chem. Soc. 2009, 131:1195-1207.
99. Ebadi M., Elsayed M.A., Aly M.H. The importance of zinc and metallothionein in brain. Biol. Signals 1994, 3:123-126.
100. Egana J.T., Zambrano C., Nunez M.T., Gonzalez-Billault C., Maccioni R.B. Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals 2003, 16:215-223.
101. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell. Biol. 2003, 160:113-123.
102. Ekmekcioglu C. The role of trace elements for the health of elderly individuals. Nahrung 2001, 45:309-316.
103. El Meskini R., Crabtree K.L., Cline L.B., Mains R.E., Eipper B.A., Ronnett G.V. ATP7A (Menkes protein) functions in axonal targeting and synaptogenesis. Mol. Cell. Neurosci. 2007, 34:409-421.
104. Faller P., Hureau C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans. 2009, 1080-1094.
105. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4162-4167.
106. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., Zhang J.T. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal. Res. 2004, 37:129-136.
107. Flagstad T. Intestinal absorption of 65 Zinc in A46 (Adema disease) after treatment with oxychinolines. Nord. Vet. Med. 1977, 29:96-100.
108. Franz K.J. Copper shares a piece of the pi. Nat. Chem. Biol. 2008, 4:85-86.
109. Frausto da Silva J.J.R., Williams R.J.P. The Biological Chemistry of the Elements 2001, Oxford University Press, Oxford.
110. Frederickson C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. 1989, 31:145-238.
111. Frederickson C.J., Koh J.Y., Bush A.I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 2005, 6:449-462.
112. Friedlich A.L., Lee J.Y., van Groen T., Cherny R.A., Volitakis I., Cole T.B., Palmiter R.D., Koh J.Y., Bush A.I. Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J. Neurosci. 2004, 24:3453-3459.
113. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 1997, 38:1155-1160.
114. Gaggelli E., Grzonka Z., Kozlowski H., Migliorini C., Molteni E., Valensin D., Valensin G. Structural features of the Cu(II) complex with the rat Abeta(1-28) fragment. Chem. Commun. (Camb.) 2008, 341-343.
115. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest. 2005, 115:1121-1129.
116. Garzon-Rodriguez W., Yatsimirsky A.K., Glabe C.G. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's A beta peptide studied by fluorescence. Bioorg. Med. Chem. Lett. 1999, 9:2243-2248.
117. Ghribi O., Golovko M.Y., Larsen B., Schrag M., Murphy E.J. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem. 2006, 99:438-449.
118. Giese A., Buchholz M., Herms J., Kretzschmar H.A. Mouse brain synaptosomes accumulate copper-67 efficiently by two distinct processes independent of cellular prion protein. J. Mol. Neurosci. 2005, 27:347-354.
119. Gomis-Ruth F.X. Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotechnol. 2003, 24:157-202.
120. Gonzales P.E., Solomon A., Miller A.B., Leesnitzer M.A., Sagi I., Milla M.E. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J. Biol. Chem. 2004, 279:31638-31645.
121. Goodman L. Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J. Nerv. Ment. Dis. 1953, 118:97-130.
122. Green M.A., Klippenstein D.L., Tennison J.R. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J. Nucl. Med. 1988, 29:1549-1557.
123. Grundke-Iqbal I., Fleming J., Tung Y.C., Lassmann H., Iqbal K., Joshi J.G. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. 1990, 81:105-110.
124. Guengerich F.P. Thematic minireview series: metals in biology. J. Biol. Chem. 2009, 284:18557.
125. Gupta V.B., Anitha S., Hegde M.L., Zecca L., Garruto R.M., Ravid R., Shankar S.K., Stein R., Shanmugavelu P., Jagannatha Rao K.S. Aluminium in Alzheimer's disease: are we still at a crossroad?. Cell Mol. Life Sci. 2005, 62:143-158.
126. Ha C., Ryu J., Park C.B. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry 2007, 46:6118-6125.
127. Haeffner F., Smith D.G., Barnham K.J., Bush A.I. Model studies of cholesterol and ascorbate oxidation by copper complexes: relevance to Alzheimer's disease beta-amyloid metallochemistry. J. Inorg. Biochem. 2005, 99:2403-2422.
128. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958, 3:41-51.
129. Hardy P.A., Gash D., Yokel R., Andersen A., Ai Y., Zhang Z. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J. Magn. Reson. Imaging 2005, 21:118-127.
130. Harris F.M., Brecht W.J., Xu Q., Mahley R.W., Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J. Biol. Chem. 2004, 279:44795-44801.
131. Hart P.J., Nersissian A.M., Herrmann R.G., Nalbandyan R.M., Valentine J.S., Eisenberg D. A missing link in cupredoxins: crystal structure of cucumber stellacyanin at 1.6 A resolution. Protein Sci. 1996, 5:2175-2183.
132. Hayakawa M., Miyashita H., Sakamoto I., Kitagawa M., Tanaka H., Yasuda H., Karin M., Kikugawa K. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J. 2003, 22:3356-3366.
133. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 1998, 18:8126-8132.
134. Hesse L., Beher D., Masters C.L., Multhaup G. The beta A4 amyloid precursor protein binding to copper. FEBS Lett. 1994, 349:109-116.
135. Himes R.A., Park G.Y., Siluvai G.S., Blackburn N.J., Karlin K.D. Structural studies of copper(I) complexes of amyloid-beta peptide fragments: formation of two-coordinate bis(histidine) complexes. Angew. Chem. Int. Ed. Engl. 2008, 47:9084-9087.
136. Hoke D.E., Tan J.L., Ilaya N.T., Culvenor J.G., Smith S.J., White A.R., Masters C.L., Evin G.M. In vitro gamma-secretase cleavage of the Alzheimer's amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc. FEBS J. 2005, 272:5544-5557.
137. Hou L., Zagorski M.G. NMR reveals anomalous copper(II) binding to the amyloid Abeta peptide of Alzheimer's disease. J. Am. Chem. Soc. 2006, 128:9260-9261.
138. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38:7609-7616.
139. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Tanzi R.E., Bush A.I. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J. Biol. Inorg. Chem. 2004, 9:954-960.
140. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Vonsattel J.P., Tanzi R.E., Bush A.I. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 1997, 272:26464-26470.
141. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., Bush A.I. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 1999, 274:37111-37116.
142. Hung Y.H., Robb E.L., Volitakis I., Ho M., Evin G., Li Q.X., Culvenor J.G., Masters C.L., Cherny R.A., Bush A.I. Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. J. Biol. Chem. 2009, 284:21899-21907.
143. Hureau C., Balland V., Coppel Y., Solari P.L., Fonda E., Faller P. Importance of dynamical processes in the coordination chemistry and redox conversion of copper amyloid-beta complexes. J. Biol. Inorg. Chem. 2009, 14:995-1000.
144. Hureau C., Faller P. Abeta-mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease. Biochimie 2009, 91:1212-1217.
145. Iskra M., Patelski J., Majewski W. Concentrations of calcium, magnesium, zinc and copper in relation to free fatty acids and cholesterol in serum of atherosclerotic men. J. Trace Elem. Electrolytes Health Dis. 1993, 7:185-188.
146. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., Saido T.C. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292:1550-1552.
147. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
148. Jefferies W.A., Dickstein D.L., Ujiie M. Assessing p97 as an Alzheimer's disease serum biomarker. J. Alzheimers Dis. 2001, 3:339-344.
149. Jiang D., Men L., Wang J., Zhang Y., Chickenyen S., Wang Y., Zhou F. Redox reactions of copper complexes formed with different beta-amyloid peptides and their neuropathological [correction of neuropathalogical] relevance. Biochemistry 2007, 46:9270-9282.
150. Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 2003, 350:113-116.
151. Karr J.W., Akintoye H., Kaupp L.J., Szalai V.A. N-Terminal deletions modify the Cu2+ binding site in amyloid-beta. Biochemistry 2005, 44:5478-5487.
152. Karr J.W., Szalai V.A. Role of aspartate-1 in Cu(II) binding to the amyloid-beta peptide of Alzheimer's disease. J. Am. Chem. Soc. 2007, 129:3796-3797.
153. Karr J.W., Szalai V.A. Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's disease amyloid-beta peptide. Biochemistry 2008, 47:5006-5016.
154. Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J. Alzheimers Dis. 2005, 8:171-182. discussion 209-115.
155. Kawahara M., Muramoto K., Kobayashi K., Mori H., Kuroda Y. Aluminum promotes the aggregation of Alzheimer's amyloid beta-protein in vitro. Biochem. Biophys. Res. Commun. 1994, 198:531-535.
156. Ke Y., Qian Z.M. Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 2007, 83:149-173.
157. Keberle H. The Biochemistry of Desferrioxamine and Its Relation to Iron Metabolism. Ann. N. Y. Acad. Sci. 1964, 119:758-768.
158. Kikinis Z., Eisenstein R.S., Bettany A.J., Munro H.N. Role of RNA secondary structure of the iron-responsive element in translational regulation of ferritin synthesis. Nucleic Acids Res. 1995, 23:4190-4195.
159. King C.E., Adlard P.A., Dickson T.C., Vickers J.C. Neuronal response to physical injury and its relationship to the pathology of Alzheimer's disease. Clin. Exp. Pharmacol. Physiol. 2000, 27:548-552.
160. Kotaki H., Yamamura Y., Tanimura Y., Saitoh Y., Nakagawa F., Tamura Z. Determination of chinoform and its metabolites in plasma by gas chromatography--mass spectrometry. Chem. Pharm. Bull. (Tokyo) 1983, 31:299-304.
161. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3922-3927.
162. Lee J.Y., Cole T.B., Palmiter R.D., Suh S.W., Koh J.Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7705-7710.
163. Lee J.Y., Friedman J.E., Angel I., Kozak A., Koh J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol. Aging 2004, 25:1315-1321.
164. Lee J.Y., Kim J.H., Hong S.H., Cherny R.A., Bush A.I., Palmiter R.D., Koh J.Y. Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. J. Biol. Chem. 2004, 279:8602-8607.
165. Lehmann D.J., Worwood M., Ellis R., Wimhurst V.L., Merryweather-Clarke A.T., Warden D.R., Smith A.D., Robson K.J. Iron genes, iron load and risk of Alzheimer's disease. J. Med. Genet. 2006, 43:e52.
166. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
167. LeVine S.M. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. 1997, 760:298-303.
168. Liewendahl K., Lamberg B.A. Metabolism of 125-iodochloroxyquinoline in man. I. Absorption, binding and excretion. Nucl. Med. (Stuttg.) 1967, 6:20-31.
169. Lind S.E., McDonagh J.R., Smith C.J. Oxidative inactivation of plasmin and other serine proteases by copper and ascorbate. Blood 1993, 82:1522-1531.
170. Ling Y., Morgan K., Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int. J. Biochem. Cell Biol. 2003, 35:1505-1535.
171. Linkous D.H., Adlard P.A., Wanschura P.B., Conko K.M., Flinn J.M. The effects of enhanced zinc on spatial memory and plaque formation in transgenic mice. J. Alzheimers Dis. 2009.
172. Linkous D.H., Flinn J.M., Koh J.Y., Lanzirotti A., Bertsch P.M., Jones B.F., Giblin L.J., Frederickson C.J. Evidence that the ZNT3 protein controls the total amount of elemental zinc in synaptic vesicles. J. Histochem. Cytochem. 2008, 56:3-6.
173. Liu S.F., Ye X., Malik A.B. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 1999, 100:1330-1337.
174. Lloret A., Badia M.C., Mora N.J., Pallardo F.V., Alonso M.D., Vina J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis. 2009, 17:143-149.
175. Loeffler D.A., LeWitt P.A., Juneau P.L., Sima A.A., Nguyen H.U., DeMaggio A.J., Brickman C.M., Brewer G.J., Dick R.D., Troyer M.D., Kanaley L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 1996, 738:265-274.
176. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 1998, 158:47-52.
177. Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., Martin L., Louis J.C., Yan Q., Richards W.G., Citron M., Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 2001, 4:231-232.
178. Lyubartseva G., Smith J.L., Markesbery W.R., Lovell M.A. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol 2009.
179. Ma Q., Li Y., Du J., Liu H., Kanazawa K., Nemoto T., Nakanishi H., Zhao Y. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2006, 27:841-849.
180. Ma Q.F., Li Y.M., Du J.T., Kanazawa K., Nemoto T., Nakanishi H., Zhao Y.F. Binding of copper (II) ion to an Alzheimer's tau peptide as revealed by MALDI-TOF MS, CD, and NMR. Biopolymers 2005, 79:74-85.
181. Madaric A., Ginter E., Kadrabova J. Serum copper, zinc and copper/zinc ratio in males: influence of aging. Physiol. Res. 1994, 43:107-111.
182. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
183. Mainous A.G., Eschenbach S.L., Wells B.J., Everett C.J., Gill J.M. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: results from an 18-year population-based cohort. Fam. Med. 2005, 37:36-42.
184. Malm T.M., Iivonen H., Goldsteins G., Keksa-Goldsteine V., Ahtoniemi T., Kanninen K., Salminen A., Auriola S., Van Groen T., Tanila H., Koistinaho J. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J. Neurosci. 2007, 27:3712-3721.
185. Markesbery W.R., Lovell M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch. Neurol. 2007, 64:954-956.
186. Martin W.R., Ye F.Q., Allen P.S. Increasing striatal iron content associated with normal aging. Mov. Disord. 1998, 13:281-286.
187. Martinez Lista E., Sole J., Arola L., Mas A. Changes in plasma copper and zinc during rat development. Biol. Neonate 1993, 64:47-52.
188. Masters C.L., Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 2006, 129:2823-2839.
189. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 2003, 85:1101-1108.
190. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
191. Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21:455-462.
192. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., Masters C.L., Li Q.X., Bush A.I. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J. Inorg. Biochem. 2006, 100:952-962.
193. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., White A.R., Beyreuther K., Masters C.L., Bush A.I., Li Q.X. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 2002, 277:44670-44676.
194. McColl G., Roberts B.R., Gunn A.P., Perez K.A., Tew D.J., Masters C.L., Barnham K.J., Cherny R.A., Bush A.I. The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J. Biol. Chem. 2009, 284:22697-22702.
195. McDermott J.R., Smith A.I., Iqbal K., Wisniewski H.M. Brain aluminum in aging and Alzheimer disease. Neurology 1979, 29:809-814.
196. McMaster D., McCrum E., Patterson C.C., Kerr M.M., O'Reilly D., Evans A.E., Love A.H. Serum copper and zinc in random samples of the population of Northern Ireland. Am. J. Clin. Nutr. 1992, 56:440-446.
197. Mekmouche Y., Coppel Y., Hochgrafe K., Guilloreau L., Talmard C., Mazarguil H., Faller P. Characterization of the ZnII binding to the peptide amyloid-beta1-16 linked to Alzheimer's disease. Chembiochemistry 2005, 6:1663-1671.
198. Meloni G., Sonois V., Delaine T., Guilloreau L., Gillet A., Teissie J., Faller P., Vasak M. Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat. Chem. Biol. 2008, 4:366-372.
199. Menditto A., Morisi G., Alimonti A., Caroli S., Petrucci F., Spagnolo A., Menotti A. Association of serum copper and zinc with serum electrolytes and with selected risk factors for cardiovascular disease in men aged 55-75 years. NFR Study Group. J. Trace Elem. Electrolytes Health Dis. 1993, 7:251-253.
200. Mercer J.F. The molecular basis of copper-transport diseases. Trends Mol. Med. 2001, 7:64-69.
201. Metodiewa D. Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 1998, 14:181-187.
202. Migliore L., Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. 2009, 667:82-97.
203. Milne D.B., Johnson P.E. Assessment of copper status: effect of age and gender on reference ranges in healthy adults. Clin. Chem. 1993, 39:883-887.
204. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 1996, 14:55-61.
205. Moir R.D., Atwood C.S., Romano D.M., Laurans M.H., Huang X., Bush A.I., Smith J.D., Tanzi R.E. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 1999, 38:4595-4603.
206. Molina J.A., Jimenez-Jimenez F.J., Aguilar M.V., Meseguer I., Mateos-Vega C.J., Gonzalez-Munoz M.J., de Bustos F., Porta J., Orti-Pareja M., Zurdo M., Barrios E., Martinez-Para M.C. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J. Neural. Transm. 1998, 105:479-488.
207. Monget A.L., Galan P., Preziosi P., Keller H., Bourgeois C., Arnaud J., Favier A., Hercberg S. Micronutrient status in elderly people. Geriatrie/Min. Vit. Aux Network. Int. J. Vitam. Nutr. Res. 1996, 66:71-76.
208. Morris C.M., Keith A.B., Edwardson J.A., Pullen R.G. Uptake and distribution of iron and transferrin in the adult rat brain. J. Neurochem. 1992, 59:300-306.
209. Morris C.M., Kerwin J.M., Edwardson J.A. Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 1994, 3:267-275.
210. Morris M.C., Evans D.A., Tangney C.C., Bienias J.L., Schneider J.A., Wilson R.S., Scherr P.A. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch. Neurol. 2006, 63:1085-1088.
211. Munro H.N., Suter P.M., Russell R.M. Nutritional requirements of the elderly. Annu. Rev. Nutr. 1987, 7:23-49.
212. Murray I.V., Liu L., Komatsu H., Uryu K., Xiao G., Lawson J.A., Axelsen P.H. Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J. Biol. Chem. 2007, 282:9335-9345.
213. Murray I.V., Sindoni M.E., Axelsen P.H. Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry 2005, 44:12606-12613.
214. Nadal R.C., Rigby S.E., Viles J.H. Amyloid beta-Cu2+ complexes in both monomeric and fibrillar forms do not generate H2O2 catalytically but quench hydroxyl radicals. Biochemistry 2008, 47:11653-11664.
215. Nagano S., Huang X., Moir R.D., Payton S.M., Tanzi R.E., Bush A.I. Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease. J. Biol. Chem. 2004, 279:14673-14678.
216. Nakano E., Williamson M.P., Williams N.H., Powers H.J. Copper-mediated LDL oxidation by homocysteine and related compounds depends largely on copper ligation. Biochim. Biophys. Acta 2004, 1688:33-42.
217. Namekata K., Imagawa M., Terashi A., Ohta S., Oyama F., Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum. Genet. 1997, 101:126-129.
218. Neldner K.H., Hambidge K.M. Zinc therapy of acrodermatitis enteropathica. N. Engl. J. Med. 1975, 292:879-882.
219. Nelson T.J., Alkon D.L. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 2005, 280:7377-7387.
220. Niciu M.J., Ma X.M., El Meskini R., Pachter J.S., Mains R.E., Eipper B.A. Altered ATP7A expression and other compensatory responses in a murine model of Menkes disease. Neurobiol. Dis. 2007, 27:278-291.
221. Nurmi A., Goldsteins G., Narvainen J., Pihlaja R., Ahtoniemi T., Grohn O., Koistinaho J. Antioxidant pyrrolidine dithiocarbamate activates Akt-GSK signaling and is neuroprotective in neonatal hypoxia-ischemia. Free Radic. Biol. Med. 2006, 40:1776-1784.
222. Oken B.S., Storzbach D.M., Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 1998, 55:1409-1415.
223. Omar R.A., Chyan Y.J., Andorn A.C., Poeggeler B., Robakis N.K., Pappolla M.A. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J. Alzheimers Dis. 1999, 1:139-145.
224. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., Cappai R., Masters C.L., Tanzi R.E., Inestrosa N.C., Bush A.I. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 2002, 277:40302-40308.
225. Opazo C., Luza S., Villemagne V.L., Volitakis I., Rowe C., Barnham K.J., Strozyk D., Masters C.L., Cherny R.A., Bush A.I. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell 2006, 5:69-79.
226. Osterman P.O. Myelopathy after clioquinol treatment. Lancet 1971, 2:544.
227. Ostrakhovitch E.A., Lordnejad M.R., Schliess F., Sies H., Klotz L.O. Copper ions strongly activate the phosphoinositide-3-kinase/Akt pathway independent of the generation of reactive oxygen species. Arch. Biochem. Biophys. 2002, 397:232-239.
228. Paik S.R., Lee J.H., Kim D.H., Chang C.S., Kim J. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Arch. Biochem. Biophys. 1997, 344:325-334.
229. Palmiter R.D., Cole T.B., Quaife C.J., Findley S.D. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14934-14939.
230. Park I.H., Jung M.W., Mori H., Mook-Jung I. Zinc enhances synthesis of presenilin 1 in mouse primary cortical culture. Biochem. Biophys. Res. Commun. 2001, 285:680-688.
231. Perluigi M., Joshi G., Sultana R., Calabrese V., De Marco C., Coccia R., Butterfield D.A. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress. Neuroscience 2006, 138:1161-1170.
232. Petri S., Calingasan N.Y., Alsaied O.A., Wille E., Kiaei M., Friedman J.E., Baranova O., Chavez J.C., Beal M.F. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2007, 102:991-1000.
233. Phinney A.L., Drisaldi B., Schmidt S.D., Lugowski S., Coronado V., Liang Y., Horne P., Yang J., Sekoulidis J., Coomaraswamy J., Chishti M.A., Cox D.W., Mathews P.M., Nixon R.A., Carlson G.A., St George-Hyslop P., Westaway D. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14193-14198.
234. Pierson K.B., Evenson M.A. 200 Kd neurofilament protein binds Al, Cu and Zn. Biochem. Biophys. Res. Commun. 1988, 152:598-604.
235. Pinero D.J., Hu J., Connor J.R. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell Mol. Biol. (Noisy-le-grand) 2000, 46:761-776.
236. Puglielli L., Friedlich A.L., Setchell K.D., Nagano S., Opazo C., Cherny R.A., Barnham K.J., Wade J.D., Melov S., Kovacs D.M., Bush A.I. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J. Clin. Invest. 2005, 115:2556-2563.
237. Qian Y., Tiffany-Castiglioni E., Welsh J., Harris E.D. Copper efflux from murine microvascular cells requires expression of the menkes disease Cu-ATPase. J. Nutr. 1998, 128:1276-1282.
238. Quinta-Ferreira M.E., Matias C.M. Tetanically released zinc inhibits hippocampal mossy fiber calcium, zinc and synaptic responses. Brain Res. 2005, 1047:1-9.
239. Rae T.D., Schmidt P.J., Pufahl R.A., Culotta V.C., O'Halloran T.V. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999, 284:805-808.
240. Raman B., Ban T., Yamaguchi K., Sakai M., Kawai T., Naiki H., Goto Y. Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide. J. Biol. Chem. 2005, 280:16157-16162.
241. Rauk A. The chemistry of Alzheimer's disease. Chem. Soc. Rev. 2009, 38:2698-2715.
242. Ravaglia G., Forti P., Maioli F., Nesi B., Pratelli L., Savarino L., Cucinotta D., Cavalli G. Blood micronutrient and thyroid hormone concentrations in the oldest-old. J. Clin. Endocrinol. Metab. 2000, 85:2260-2265.
243. Regland B., Lehmann W., Abedini I., Blennow K., Jonsson M., Karlsson I., Sjogren M., Wallin A., Xilinas M., Gottfries C.G. Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cogn. Disord. 2001, 12:408-414.
244. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M.B., Weinreb O., Mandel S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. 2006, 97:527-536.
245. Ridge P.G., Zhang Y., Gladyshev V.N. Comparative genomic analyses of copper transporters and cuproproteomes reveal evolutionary dynamics of copper utilization and its link to oxygen. PLoS One 2008, 3:e1378.
246. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60:1685-1691.
247. Robson K.J., Lehmann D.J., Wimhurst V.L., Livesey K.J., Combrinck M., Merryweather-Clarke A.T., Warden D.R., Smith A.D. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J. Med. Genet. 2004, 41:261-265.
248. Rogers J.T., Randall J.D., Cahill C.M., Eder P.S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S.S., Utsuki T., Greig N.H., Lahiri D.K., Tanzi R.E., Bush A.I., Giordano T., Gullans S.R. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277:45518-45528.
249. Roskams A.J., Connor J.R. Iron, transferrin, and ferritin in the rat brain during development and aging. J. Neurochem. 1994, 63:709-716.
250. Rozga M., Bal W. The Cu(II)/Abeta/human serum albumin model of control mechanism for copper-related amyloid neurotoxicity. Chem. Res. Toxicol. 2009, 23:298-308.
251. Rozga M., Protas A.M., Jablonowska A., Dadlez M., Bal W. The Cu(II) complex of Abeta40 peptide in ammonium acetate solutions. Evidence for ternary species formation. Chem. Commun. (Camb.) 2009, 1374-1376.
252. Sacharczuk M., Zagulski T., Sadowski B., Barcikowska M., Pluta R. Lactoferrin in the central nervous system. Neurol. Neurochir. Pol. 2005, 39:482-489.
253. Sayre L.M., Perry G., Harris P.L., Liu Y., Schubert K.A., Smith M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 2000, 74:270-279.
254. Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D., Bayer T.A., Beyreuther K., Multhaup G. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J. Biol. Chem. 2001, 276:33923-33929.
255. Schlief M.L., Craig A.M., Gitlin J.D. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J. Neurosci. 2005, 25:239-246.
256. Schlief M.L., West T., Craig A.M., Holtzman D.M., Gitlin J.D. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14919-14924.
257. Schneider A., Rajendran L., Honsho M., Gralle M., Donnert G., Wouters F., Hell S.W., Simons M. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 2008, 28:2874-2882.
258. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res. 2005, 2:541-551.
259. Schreck R., Meier B., Mannel D.N., Droge W., Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 1992, 175:1181-1194.
260. Scott L.E., Orvig C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem. Rev. 2009, 109:4885-4910.
261. Sensi S.L., Paoletti P., Bush A.I., Sekler I. Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci. 2009, 10:780-791.
262. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346:476-483.
263. Shearer J., Szalai V.A. The amyloid-beta peptide of Alzheimer's disease binds Cu(I) in a linear bis-his coordination environment: insight into a possible neuroprotective mechanism for the amyloid-beta peptide. J. Am. Chem. Soc. 2008, 130:17826-17835.
264. Shimada Y., Tsuji T., Igata A., Steinitz H. Halogenated oxyquinoline derivatives and neurological syndromes. Lancet 1971, 2:41-43.
265. Shin R.W., Kruck T.P., Murayama H., Kitamoto T. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res. 2003, 961:139-146.
266. Shinall H., Song E.S., Hersh L.B. Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 2005, 44:15345-15350.
267. Shishodia S., Sethi G., Aggarwal B.B. Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci. 2005, 1056:206-217.
268. Siddiq A., Ayoub I.A., Chavez J.C., Aminova L., Shah S., LaManna J.C., Patton S.M., Connor J.R., Cherny R.A., Volitakis I., Bush A.I., Langsetmo I., Seeley T., Gunzler V., Ratan R.R. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J. Biol. Chem. 2005, 280:41732-41743.
269. Silvestri L., Camaschella C. A potential pathogenetic role of iron in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:1548-1550.
270. Simons A., Ruppert T., Schmidt C., Schlicksupp A., Pipkorn R., Reed J., Masters C.L., White A.R., Cappai R., Beyreuther K., Bayer T.A., Multhaup G. Evidence for a copper-binding superfamily of the amyloid precursor protein. Biochemistry 2002, 41:9310-9320.
271. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S.M., Wang S., Walker D., Zhao J., McConlogue L., John V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402:537-540.
272. Smart T.G., Hosie A.M., Miller P.S. Zn2+ ions: modulators of excitatory and inhibitory synaptic activity. Neuroscientist 2004, 10:432-442.
273. Smith D.G., Cappai R., Barnham K.J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 2007, 1768:1976-1990.
274. Smith D.P., Smith D.G., Curtain C.C., Boas J.F., Pilbrow J.R., Ciccotosto G.D., Lau T.L., Tew D.J., Perez K., Wade J.D., Bush A.I., Drew S.C., Separovic F., Masters C.L., Cappai R., Barnham K.J. Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J. Biol. Chem. 2006, 281:15145-15154.
275. Smith J.L., Xiong S., Lovell M.A. 4-Hydroxynonenal disrupts zinc export in primary rat cortical cells. Neurotoxicology 2006, 27:1-5.
276. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
277. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997, 17:2653-2657.
278. Sohal R.S., Wennberg-Kirch E., Jaiswal K., Kwong L.K., Forster M.J. Effect of age and caloric restriction on bleomycin-chelatable and nonheme iron in different tissues of C57BL/6 mice. Free Radic. Biol. Med. 1999, 27:287-293.
279. Sparks D.L., Schreurs B.G. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11065-11069.
280. Squitti R., Lupoi D., Pasqualetti P., Dal Forno G., Vernieri F., Chiovenda P., Rossi L., Cortesi M., Cassetta E., Rossini P.M. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002, 59:1153-1161.
281. Squitti R., Pasqualetti P., Dal Forno G., Moffa F., Cassetta E., Lupoi D., Vernieri F., Rossi L., Baldassini M., Rossini P.M. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005, 64:1040-1046.
282. Squitti R., Rossini P.M., Cassetta E., Moffa F., Pasqualetti P., Cortesi M., Colloca A., Rossi L., Finazzi-Agro A. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur. J. Clin. Invest. 2002, 32:51-59.
283. Stoltenberg M., Bush A.I., Bach G., Smidt K., Larsen A., Rungby J., Lund S., Doering P., Danscher G. Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 2007, 150:357-369.
284. Su X.Y., Wu W.H., Huang Z.P., Hu J., Lei P., Yu C.H., Zhao Y.F., Li Y.M. Hydrogen peroxide can be generated by tau in the presence of Cu(II). Biochem. Biophys. Res. Commun. 2007, 358:661-665.
285. Suh J.H., Moreau R., Heath S.H., Hagen T.M. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005, 10:52-60.
286. Suh S.W., Jensen K.B., Jensen M.S., Silva D.S., Kesslak P.J., Danscher G., Frederickson C.J. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 2000, 852:274-278.
287. Suh Y.H., Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 2002, 54:469-525.
288. Sullivan P.G., Brown M.R. Mitochondrial aging and dysfunction in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:407-410.
289. Syme C.D., Nadal R.C., Rigby S.E., Viles J.H. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques. J. Biol. Chem. 2004, 279:18169-18177.
290. Syme C.D., Viles J.H. Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease. Biochim. Biophys. Acta 2006, 1764:246-256.
291. Szallasi Z., Bogi K., Gohari S., Biro T., Acs P., Blumberg P.M. Non-equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells. J. Biol. Chem. 1996, 271:18299-18301.
292. Tabner B.J., Turnbull S., El-Agnaf O.M., Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 2002, 32:1076-1083.
293. Takeda A. Essential trace metals and brain function. Yakugaku Zasshi 2004, 124:577-585.
294. Takeda A., Minami A., Takefuta S., Tochigi M., Oku N. Zinc homeostasis in the brain of adult rats fed zinc-deficient diet. J. Neurosci. Res. 2001, 63:447-452.
295. Tapiero H., Townsend D.M., Tew K.D. Trace elements in human physiology and pathology. Copper. Biomed. Pharmacother. 2003, 57:386-398.
296. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 1996, 55:1023-1025.
297. Torsdottir G., Kristinsson J., Sveinbjornsdottir S., Snaedal J., Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol. Toxicol. 1999, 85:239-243.
298. Tsubaki T., Honma Y., Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1971, 1:696-697.
299. Ujiie M., Dickstein D.L., Jefferies W.A. p97 as a biomarker for Alzheimer disease. Front Biosci. 2002, 7:e42-47.
300. Valensin D., Mancini F.M., Luczkowski M., Janicka A., Wisniewska K., Gaggelli E., Valensin G., Lankiewicz L., Kozlowski H. Identification of a novel high affinity copper binding site in the APP(145-155) fragment of amyloid precursor protein. Dalton Trans. 2004, 16-22.
301. Vallee B.L., Coleman J.E., Auld D.S. Zinc fingers, zinc clusters, and zinc twists in DNA-binding protein domains. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:999-1003.
302. Vasak M., Hasler D.W. Metallothioneins: new functional and structural insights. Curr. Opin. Chem. Biol. 2000, 4:177-183.
303. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
304. Vaughan D.W., Peters A. The structure of neuritic plaque in the cerebral cortex of aged rats. J. Neuropathol. Exp. Neurol. 1981, 40:472-487.
305. Venti A., Giordano T., Eder P., Bush A.I., Lahiri D.K., Greig N.H., Rogers J.T. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann. N. Y. Acad. Sci. 2004, 1035:34-48.
306. Viles J.H., Cohen F.E., Prusiner S.B., Goodin D.B., Wright P.E., Dyson H.J. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2042-2047.
307. Vyas S.B., Duffy L.K. Stabilization of secondary structure of Alzheimer beta-protein by aluminum(III) ions and D-Asp substitutions. Biochem. Biophys. Res. Commun. 1995, 206:718-723.
308. Wang D.S., Iwata N., Hama E., Saido T.C., Dickson D.W. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 2003, 310:236-241.
309. Watanabe S., Nagano S., Duce J., Kiaei M., Li Q.X., Tucker S.M., Tiwari A., Brown R.H., Beal M.F., Hayward L.J., Culotta V.C., Yoshihara S., Sakoda S., Bush A.I. Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2007, 42:1534-1542.
310. Wender M., Szczech J., Hoffmann S., Hilczer W. Electron paramagnetic resonance analysis of heavy metals in the aging human brain. Neuropatol. Pol. 1992, 30:65-72.
311. West D.X., Liberta A.E., Rajendran K.G., Hall I.H. The cytotoxicity of copper(II) complexes of heterocyclic thiosemicarbazones and 2-substituted pyridine N-oxides. Anticancer Drugs 1993, 4:241-249.
312. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 2006, 281:17670-17680.
313. White A.R., Reyes R., Mercer J.F., Camakaris J., Zheng H., Bush A.I., Multhaup G., Beyreuther K., Masters C.L., Cappai R. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 1999, 842:439-444.
314. Whitson J.S., Selkoe D.J., Cotman C.W. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 1989, 243:1488-1490.
315. Wu J., Basha M.R., Brock B., Cox D.P., Cardozo-Pelaez F., McPherson C.A., Harry J., Rice D.C., Maloney B., Chen D., Lahiri D.K., Zawia N.H. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J. Neurosci. 2008, 28:3-9.
316. Wu W., Graves L.M., Jaspers I., Devlin R.B., Reed W., Samet J.M. Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am. J. Physiol. 1999, 277:L924-931.
317. Xie C.X., Mattson M.P., Lovell M.A., Yokel R.A. Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons. Brain Res. 1996, 743:271-277.
318. Xu N., Majidi V., Markesbery W.R., Ehmann W.D. Brain aluminum in Alzheimer's disease using an improved GFAAS method. Neurotoxicology 1992, 13:735-743.
319. Yamamoto A., Shin R.W., Hasegawa K., Naiki H., Sato H., Yoshimasu F., Kitamoto T. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 2002, 82:1137-1147.
320. Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., Brashier J.R., Stratman N.C., Mathews W.R., Buhl A.E., Carter D.B., Tomasselli A.G., Parodi L.A., Heinrikson R.L., Gurney M.E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999, 402:533-537.
321. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
322. Yassin M.S., Ekblom J., Lofberg C., Oreland L. Transmethylation reactions and autoradiographic distribution of vitamin B12: effects of clioquinol treatment in mice. Jpn. J. Pharmacol. 1998, 78:55-61.
323. Yassin M.S., Ekblom J., Xilinas M., Gottfries C.G., Oreland L. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J. Neurol. Sci. 2000, 173:40-44.
324. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998, 21:75-80.
325. Yoshiike Y., Tanemura K., Murayama O., Akagi T., Murayama M., Sato S., Sun X., Tanaka N., Takashima A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J. Biol. Chem. 2001, 276:32293-32299.
326. Yoshimoto N., Tasaki M., Shimanouchi T., Umakoshi H., Kuboi R. Oxidation of cholesterol catalyzed by amyloid beta-peptide (Abeta)-Cu complex on lipid membrane. J. Biosci. Bioeng. 2005, 100:455-459.
327. Yu W.H., Lukiw W.J., Bergeron C., Niznik H.B., Fraser P.E. Metallothionein III is reduced in Alzheimer's disease. Brain Res. 2001, 894:37-45.
328. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88.
329. Zatta P., Tognon G., Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J. Pineal. Res. 2003, 35:98-103.
330. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 2001, 76:1766-1773.
331. Zhang A.S., Enns C.A. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J. Biol. Chem. 2009, 284:711-715.
332. Zhang X., Luhrs K.J., Ryff K.A., Malik W.T., Driscoll M.J., Culver B. Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS1dE9 mice. Neuroscience 2009, 161:53-58.
333. Zhou L.X., Du J.T., Zeng Z.Y., Wu W.H., Zhao Y.F., Kanazawa K., Ishizuka Y., Nemoto T., Nakanishi H., Li Y.M. Copper (II) modulates in vitro aggregation of a tau peptide. Peptides 2007, 28:2229-2234.
334. Zhu X., Su B., Wang X., Smith M.A., Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol. Life Sci. 2007, 64:2202-2210.